What's Happening?
Sutter Health in Northern California has developed and implemented a multidisciplinary virtual review board, known as the Advanced Therapeutics for Alzheimer’s Disease (ATAD) Review Board, to facilitate the administration of amyloid-targeting antibody
therapies for Alzheimer's disease in community settings. This model allows general neurologists to prescribe and monitor treatments like lecanemab and donanemab, while the centralized virtual board provides specialist oversight. The board, comprising cognitive neurologists, a neuroradiologist, a pharmacist, and a registered nurse program manager, evaluates diagnostic evidence, eligibility criteria, and MRI findings for amyloid-related imaging abnormalities (ARIA) risk. The local neurologist maintains responsibility for prescribing and ongoing monitoring, with the board acting as an advisory layer. From November 2023 through December 2025, the board processed 574 referrals, with 447 fully reviewed cases submitted by 51 general neurologists. Of these, 344 patients (77%) were deemed eligible for treatment, and 214 ultimately began therapy through general neurology. The safety data showed radiographic ARIA rates of 17.4% for lecanemab and 28.8% for donanemab, with symptomatic ARIA occurring in 2.6% and 1.7% of patients, respectively, which are comparable to or lower than rates in pivotal clinical trials.
Why It's Important?
This initiative is crucial for addressing the logistical challenge of delivering new Alzheimer's treatments to a broad population, especially given the severe shortage of dementia specialists in the U.S. The Sutter model demonstrates a scalable approach to expand access to these advanced therapies beyond specialized memory centers, which are often concentrated in urban areas. By empowering general neurologists with centralized expert support, it helps overcome geographical barriers and reduces waiting lists, making treatment more accessible to rural, elderly, and geographically dispersed patients. The model also functions as a learning network, allowing community clinicians to gain expertise over time, thereby enhancing the overall capacity of the healthcare system to manage complex Alzheimer's regimens. This approach could significantly impact public health by enabling more patients to receive timely and appropriate care, potentially slowing disease progression and improving quality of life for a larger segment of the affected population.
What's Next?
The Sutter model serves as a template for other health systems facing similar challenges in expanding access to specialized care. The authors propose that similar review boards could be adopted by other integrated delivery systems to maintain specialist input while decentralizing treatment administration. Future steps may involve further refinement of the virtual review board's processes, continued monitoring of long-term safety and efficacy in real-world settings, and potentially broader dissemination of this model across the nation. The success of this approach could also influence policy discussions regarding healthcare delivery for other complex conditions requiring specialized oversight but widespread access. The ongoing collection of observational outcomes will be vital for validating the model's effectiveness and safety profile over time, potentially leading to its widespread adoption and integration into national healthcare strategies.
Beyond the Headlines
The Sutter Health model highlights a fundamental shift in healthcare delivery, moving from a centralized, specialist-dependent system to a more distributed, community-based approach supported by virtual expertise. This innovation addresses not only the immediate need for Alzheimer's drug access but also broader issues of health equity and resource allocation. It underscores the potential of telemedicine and virtual collaboration to bridge gaps in specialized medical care, particularly in areas with limited access to subspecialists. The model's emphasis on training and empowering general neurologists also contributes to a more resilient and adaptable healthcare workforce. Furthermore, it raises questions about the future of medical education and continuous professional development, as community clinicians will increasingly need to manage advanced therapies with remote expert guidance. This approach could set a precedent for how integrated health systems can translate scientific advancements into practical, coordinated, and local care, ensuring patient safety remains paramount.
